Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

The FDA has approved the first drug for the treatment of moderate-to-severe Alzheimer’s disease. Memantine, a noncompetitive inhibitor of the N-methyl-D-aspartate receptor, has been available outside of the United States since 1982.

Pharmacology Update: Memantine Hydrochloride Tablets (Namenda)